ArticleCureus2026
Role of Positron Emission Tomography/Computed Tomography (PET/CT) in Detecting Metachronous Primary Tumors: Diagnostic and Clinical Implications From a Single-Patient Case.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- One patient with synchronous multiple primary colon cancers which is easy to miss: a case report.Frontiers in surgery · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metachronous primary tumors (MPTs) are defined as two or more independent primary tumors and require exclusion of metastatic disease. We report a rare case of metachronous quadruple malignancies in a 53-year-old male over a 10-year period. The patient was initially diagnosed with stage IIA colon adenocarcinoma (2014), followed by high-grade urothelial carcinoma of the left renal pelvis (2017) and non-invasive urothelial recurrence (2022). In 2023, fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) revealed a hypermetabolic left lower lobe lung mass with subcarinal nodal involvement (stage IIIB). Immunohistochemistry confirmed primary lung adenocarcinoma. The patient underwent concurrent chemoradiotherapy with a near-complete metabolic response, followed by successful lobectomy. In 2024, a fourth primary cutaneous squamous cell carcinoma was identified and excised. This case highlights the diagnostic challenge of distinguishing multiple primaries from metastatic disease and underscores the pivotal role of FDG PET/CT in staging, response assessment, and longitudinal management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.